- Market Research
- Injectable Seizure Drugs Market Segmented by Drug Type such as Fosphenytoin, Midazolam, Carbamazepine, Cenobamate, Gabapentin, Phenytoin, Lamotrigine, Topiramate, Levetiracetam, Clobazam, Diazepam having Therapy such as Monotherapy, Combination Therapy used in Generalized seizures and Focal Seizures
Global Injectable seizure drugs: Market Outlook
Injectable seizure drugs are important in treating emergencies of clinical seizure emergencies and in other treatments where oral administration is not possible. The injectable seizure drugs provide rapid and complete delivery (through blood vessels) or almost complete (muscle gain) bioavailability. Controlled administration of the injectable seizure drugs is feasible with intravenous but not intramuscular formulations. The median incidence of acute symptomatic seizures is 29–39 per 100,000 per year. Epilepsy affects nearly 3 million people in the US, with nearly 500 new cases of epilepsy diagnosed every day.
Seizures, a major symptom of epilepsy, are defined as abnormal paroxysmal electrical disturbances of cortical neural networks, many anti-epileptic drugs work in some ways that reduce neuronal excitability (sodium and calcium channel modulation) or increase inhibition of neuronal by interacting in different parts am-amino butyric acid receptors. Many injectable seizure drugs are believed to work as a result of several concomitant processes in both the excitatory and inhibitory structures
With the increasing number of epileptic seizures due to greater exposure to perinatal risk factors and higher rates of CNS disease, the injectable seizure market is the leading choice of dosage form for seizure treatment.
Find Out More about the Report Coverage
What are the factors boosting the Growth of the Injectable seizure drugs Market?
Seizures brought about by epilepsy cause 0.5% of the world's disease burden. Epilepsy has a profound impact on the economy in terms of health care needs, premature death, and lost productivity. Over 50,000 individuals in the United States die from delayed seizures consistently, either from brain damage because of the actual seizure or from mishaps identified with passing out mid-assault. Brain damage is proven to cause severe epilepsy after and after trauma in many cases which is expected to stimulate the growth of the injectable seizure market. Increasing cases of accidents and injuries are expected to stimulate the growth of the injectable seizure market in the forecasted period. As indicated by the Brain Injury Association of Michigan, brain injury is one of the major causes of partial epilepsy seizures. The ascent in the number of road accidents in improved economies can uphold the fact. The ascent in partial epilepsy seizures coming about because of brain injuries is another driver for the injectable seizure market.
The main variables influencing the development of the injectable seizure drugs market are the fact that 25% of epileptic seizures are poorly controlled, with the problem of side effects, limiting treatment doses, and the reason why 33% of patients do not adhere to their form of treatment. Price erosion as one of the factors is expected to increase access to treatment as most patients are from middle and low-income countries. Therefore, it is expected that the expansion of the injectable market will continue in the forecast period.
The number of antiepileptic drugs including seizure drugs approved for use in the United States alone has more than doubled over the past 15 years.
Focal seizures are the predominant seizure type both in children and in adults accounting for about 36% of seizures. In many low-income countries, however, the most prominent types reported are generalized tonic-clonic seizures. About 80% of people with epilepsy live in low- and middle-income countries. The estimated number of people with a recurring attack or in need of treatment at any given time is between 4 and 10 per 1000 people. These factors are expected to propel the injectable seizure market in the forecasted period.
Likewise, the developing advances in research and development of novel drugs to prevent or control genetic factors, abnormal brain growth, infection, traumatic brain injury, stroke, brain tumors are some of the factors that add to the worldwide Injectable seizure drug market.
Immediate refunds are expected to have a positive impact on both the late stages of product development and after product launch. The government is the main payer for most genetic diseases, using Medicare funds. Several reimbursements are to the extent that will affect compensation for hospital and medical providers.
Customize this Report
Explore Intelligence Tailored to Your Business Goals.
What are the Key Challenges that may restrain the Growth of the Injectable seizure drug Market?
However, some factors can hinder the growth of the global Injectable seizure drugs market growth such as marketing of an unapproved drug, recall of drug by the FDA. Furthermore, the illicit use of anti-seizure drugs impacts the global Injectable seizure drugs market and results in more stringent regulations and the lack of FDA approvals in some regions impact the global Injectable seizure drugs market growth.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
Key Segments of Injectable seizure drugs Market Covered in the Report
Based on drug type, the global Injectable seizure drugs market has been segmented as
Based on therapy type, the global Injectable seizure drugs market has been segmented as
- Combination Therapy
Based on the type of seizure, the global Injectable seizure drugs market has been segmented as
- Generalized seizures
- Absence Seizures
- Tonic-Clonic Seizures
- Focal Seizures
Based on distribution channel, the global Injectable seizure drugs market has been segmented as
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Based on region, the global Injectable seizure drugs market has been segmented as
- North America
- Latin America
- South Asia
- East Asia
- Middle East & Africa
Explore Persistence Market Research’s expertise in promulgation of the business !
Key players such as Sanofi
- Pfizer Inc.
- GW Pharmaceuticals plc
- UCB S.A.
- Eisai Co.Ltd.
- Sunovion Pharmaceuticals Inc.
- H. Lundbeck A/S
- GlaxoSmithKline plc
- Sandoz Inc.
- Omega Laboratories Ltd ERFA Canada 2012 Inc.
- Lundbeck Pharmaceuticals Llc
- Fresenius Kabi
- Mylan Pharmaceuticals
- Hoffmann La and
are actively involved in offering Injectable seizure drugs.
How Increasing R&D to Augment Injectable seizure drugs Market Growth?
The rising demand for preventing or controlling epileptic seizures is encouraging key manufacturers to invest more in research activities to develop more Injectable seizure drugs. Manufacturers are engaged in clinical trials for drug compounds to develop Injectable seizure drugs. Few of them have got the FDA approval from the regulatory bodies.
- For instance, Xeris Pharma has received FDA approval for its diazepam formulation to treat acute repetitive seizures, also known as cluster seizures for Phase III of the clinical trial.
- Sedor Pharmaceuticals, LLC, has received FDA approval for fosphenytoin sodium for injection for status epilepticus in adult and pediatric patients.
Moreover, other players including Amzell B.V and Pfizer, Inc. have their compounds under pipeline for treatment. This is one of the prime factors driving the growth of the global Injectable seizure drugs market.
What strategies are the Key Players adopting for Increasing their Market Share in the Injectable seizure drugs Market?
The Injectable seizure drugs market is set to change in the coming years, attributable to the rising awareness of the better and cost-effective treatment available in the market. Furthermore, the ideal location for the introduction of new injectable seizure drugs is expected to increase the market size of the global Injectable seizure drugs market by empowering the drug manufacturer to enter more actively into the market. Companies and academics attempting to evaluate difficulties and look for promising circumstances that could impact Injectable seizure drugs R&D. The therapies under development is centered on the novel and cost-effective approaches to treating epileptic seizures. The introduction of emerging therapies will significantly impact the global Injectable seizure drugs market.
- According to Xeris Pharma, More than 2.7 million people in the U.S. have epilepsy, with roughly 200,000 new diagnoses each year. It estimates that 30% to 40% of those patients aren't getting adequate seizure control from oral therapy, which puts them at risk for breakthrough seizures.
Why is the U.S. a Big Market for Injectable seizure drugs?
In the U.S., the medical care framework is well known for its use and progressed foundation. The state of care facilities and hospitals is governed by regulatory rules and insurance policies. The regulatory bodies and the U.S. government are adopting various cost-effective plans to reduce their healthcare burden. Increasing acceptance of novel and cost-effective treatments is likely to drive Injectable seizure drugs to demand in the country. Moreover, the presence of major players in the country and robust R&D are likely to boost the regional market. The U.S. is the most dominating country in the global Injectable seizure drugs market and is expected to continue during the forecast period.
How is the Injectable seizure drugs Market of Europe flourishing?
The European medical services framework has a developing medical services framework, with a multi-payer system that is to a great extent funded by the government. It is the second most successful healthcare system after the U.S in the world. With the presence of many key players, growing R&D in the European countries creates a huge opportunity for the Injectable seizure drugs market to grow. In Europe, at least 6 million people have epilepsy, and 15 million Europeans will have one seizure eventually in their lives. However, in some European countries, epilepsy is not perceived as a brain disorder, and up to 40% of people with this condition may be untreated. This shows a treatment gap. This treatment gap may thrust the injectable seizure drug market in Europe.
Why is India dominating the Asia Pacific in the Injectable seizure drugs Market?
About twelve million people with epilepsy are expected to live in India; which contributes about one-sixth of the global burden. The overall prevalence is (3.0-11.9 per 1,000 population) and incidence (0.2-0.6 per 1,000 population per year) of people with epilepsy in India. Since a large number of Indians lives either in rural or lower-income cities the awareness of epilepsy-related seizure is radically low. The socio-economic difference has resulted in low treatment accessibility for seizures in India which has resulted in deaths. However, improvement in health care reforms in India has upgraded admittance to a variety of treatment options thereby increasing the life span of respective populations. Injectable seizure drugs are the only option to prevent prolonged seizures. This factor is propelling the Injectable seizure drugs market in the country. Furthermore, the growing pharmaceutical companies are also contributing to the Injectable seizure drugs market growth.
What are the Restrains that MEA Face in the Injectable seizure drugs Market?
The least awareness of the seizure as a disorder has become a major restraint in the MEA region. Besides, the high cost of development and stringent regulatory approval process expects to hinder the MEA Injectable seizure drugs market growth. Lack of awareness about better treatment and prevention of involuntary consequences of prolonged seizures would cause adverse effects on injectable seizure drug market growth.
What is the Impact of the Pandemic on the Growth of the Injectable seizure drugs Market?
The emergence of COVID-19 has brought the world to a halt. The health crisis has phenomenally affected organizations across all ventures. The pandemic has shaken several industries with the complete lockdown imposed after its outbreak. The economies and industries were hampered by the mass spread of the disease, which led to a recession because of the closing down of the offices, production lines, and market. Subsequently, the demand and supplies of seizure drugs were halted, leading to a significant loss to the growth of the Injectable seizure drugs. Besides, the progression of patients in the hospitals and clinics has likewise declined, resulting in a decline in treatment rates.
The global focus of R&D was shifted onto the development of the COVID-19 vaccine, as a result, the majority of the research funds and investments were channeled for the COVID-19 vaccine development only. However, the Injectable seizure drugs demand is expected leverage from the current dip in the growth trend, with the resuming of the economies and market.
The report covers exhaustive analysis on:
- Injectable seizure drugs Market Segments
- Injectable seizure drugs Market Dynamics
- Historical Actual Market Size, 2016 - 2020
- Injectable seizure drugs market Size & Forecast 2021 to 2031
- Market Current Trends/Issues/Challenges
- Competition & Companies involved
- Market Drivers and Restraints
Regional analysis includes
- North America
- Latin America
- South Asia
- East Asia
- Middle East & Africa
- Shifting Industry dynamics
- In-depth market segmentation
- Historical, current, and projected industry size Recent industry trends
- Key Competition landscape
- Strategies for key players and product offerings
- Potential and niche segments/regions exhibiting promising growth
- A neutral perspective towards market performance
NOTE - All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of the company.